Clinical trials: Hepatitis C Virus (HCV)
Hepatitis C
Ask a Friend to Take a Test for Hepatitis C Infection
This exploratory study will carry out a respondent-driven sampling exercise, where participants will identify their previous injecting partners and contact these individuals to invite them to take an Hepatitis C test.
- Trial name
- NCT03697135
- Testing
- Respondent Driven Sampling
- Where
- United Kingdom
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- NHS Tayside
Hepatitis C, Chronic
Multiple Oral Doses of BI 207127 NA in Treatment naïve and Treatment-experienced Hepatitis C Virus (HCV)-Infected Patients
The purpose of this study was to investigate antiviral activity, safety and pharmacokinetics of 5 days of monotherapy with BI 207127 in HCV genotype 1 (GT1) infected patients.
- Trial name
- NCT02176525
- Testing
- BI 207127 NA
- Volunteers
- 75 people
- Sponsor
- Boehringer Ingelheim
Hepatitis C, Cognitive Impairment
P300 in Early Cognitive Impairment in Hepatitis C Virus
Approximately 50% of patients with hepatitis C have complaints of fatigue and cognitive deficits even before the development of significant hepatic impairment.
- Trial name
- NCT04389268
- Testing
- Visual Event-Related Potentials
- Where
- Egypt
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Mansoura University Hospital
Hepatitis C, Chronic
First in Human Study of ALS-002158; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1
This randomized, double-blind, placebo-controlled, 3-part study will assess the safety, tolerability, and pharmacokinetics of orally administered ALS-002158 in healthy volunteers (HV) and subjects with chronic hepatitis C (CHC)…
- Trial name
- NCT01554085
- Testing
- ALS-002158
- Where
- 5 sites in Australia, New Zealand
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Alios Biopharma Inc.
Hepatitis C (HCV), Acupuncture
Acupuncture as an Adjunctive Treatment for Hepatitis C Patients
Objective: to study the effect of Acupuncture on liver cirrhosis, SVR and health related quality of life in HCV patients receiving standard treatment (Peg Interferon+ Ribavirin).
- Trial name
- NCT01750515
- Testing
- Acupuncture
- Where
- Israel
- Sponsor
- Assy Nimer
Hepatitis C, Chronic
Dose Ranging of GSK2336805 in Combination Therapy
GSK2336805 is a novel hepatitis C virus (HCV) non-structural 5A (NS5A) inhibitor being developed for the treatment of chronic HCV infection.
- Trial name
- HAI115879 (NCT01648140)
- Testing
- GSK2336805 40 mg, GSK2336805 60 mg, Pegylated interferon alpha-2a
- Where
- 34 sites in United States, Belgium and 4 more
- Volunteers
- 286 people
- Sponsor
- GlaxoSmithKline
Chronic Hepatitis C Virus
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Velpatasvir in Participants With Chronic HCV Infection
The primary objective of the study is to evaluate the safety, tolerability, and antiviral activity of velpatasvir (formerly GS-5816) in HCV treatment naive participants with genotypes 1-6.
- Trial name
- NCT01740791
- Testing
- Velpatasvir
- Where
- 10 sites in United States, Puerto Rico
- Volunteers
- 103 people
- Sponsor
- Gilead Sciences
Hepatitis C
Timing and Duration of Acute Hepatitis C Treatment
Spontaneous resolution of acute hepatitis C infection cannot be predicted and the majority of cases persist and become chronic. This randomized trial assesses the efficacy and safety of peginterferon alfa-2b.
- Trial name
- NCT00241618
- Testing
- Pegylated interferon alpha 2, Ribavirin
- Where
- 3 sites in Egypt
- Volunteers
- 180 people
- Sponsor
- Ain Shams University
Hepatitis C
The Effect of Adding Metformin to the Treatment of Hepatitis C
Insulin resistance is known to adversely effect viral response to treatment in hepatitis C patients We are aiming to study the effect of an insulin sensitizer, metformin, in viral response of hepatitis C to treatment with…
- Trial name
- NCT00560690
- Testing
- Metformin, pegylated interferon, Ribavirin
- Where
- Iran
- Volunteers
- 140 people
- Sponsor
- Tehran University of Medical Sciences
Hepatitis C
Hepatitis C: Community Testing and Treatment (CT2 Study Myanmar)
Implementation-effectiveness hybrid trial assessing acceptability, feasibility and cost-effectiveness of community-based point-of-care testing and treatment for hepatitis C.
- Trial name
- CT2 (NCT03939013)
- Testing
- Xpert HCV VL
- Where
- 2 sites in Burma
- Volunteers
- 634 people, healthy volunteers welcome
- Sponsor
- Macfarlane Burnet Institute for Medical Research and Public Health Ltd
Hepatitis C, HIV Infections
Study to Reduce Intravenous Exposures (STRIVE)
The purpose of this study is to determine whether a six-session, small group behavioral intervention based on "peer-volunteer activism" is effective in (1) decreasing distributive sharing of syringes and other injection…
- Trial name
- NCT00391482
- Testing
- Peer Mentoring Intervention for HCV-Infected IDUs
- Where
- 3 sites in United States
- Volunteers
- 750 people
- Sponsor
- National Institute on Drug Abuse (NIDA)
Hepatitis C
HCV Virions Bound Proteins
The emergence of hepatocellular carcinoma (HCC) has prompted a search for a thorough understanding of the biology of one of its major causative agents, the hepatitis C virus (HCV).
- Trial name
- NCT02795403
- Testing
- blood draw of 150ml, twice
- Where
- France
- Volunteers
- 10 people
- Sponsor
- Hospices Civils de Lyon
Cirrhosis, Chronic Hepatitis C
Efficacy and Safety of Viusid in Patients With Hepatic Cirrhosis Secondary to Hepatitis C Virus Infection.
The purpose of the study is to evaluate whether Viusid, a nutritional supplement, reduce the mortality and the complications (ascites, spontaneous bacterial peritonitis, hepatorenal syndrome, hepatic encephalopathy…
- Trial name
- NCT00502086
- Testing
- Viusid (nutritional supplement)
- Where
- Cuba
- Volunteers
- 100 people
- Sponsor
- Catalysis SL
HEPATITIS C (HCV), Opioid Use Disorder
Pilot Study of an Adapted Partner Navigation Intervention Booster Session for Sustained Healthcare Engagement Among People Who Inject Drugs
This study builds upon an ongoing NIH-funded randomized controlled trial (R01DA053325) evaluating a Partner Navigation Intervention to increase hepatitis C virus (HCV) treatment initiation among young adult people who inject…
- Conditions
- HEPATITIS C (HCV), Opioid Use Disorder, Substance Use Disorder (SUD), Drug Use Disorders
- Trial name
- NCT07631559
- Testing
- Partner navigation intervention booster session
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of California, San Francisco
HEPATITIS C (HCV), Incarceration
Implementing Low-Barrier HCV Treatment in a Jail Setting
The goal of this clinical trial is to learn whether a low-barrier treatment program can help people with hepatitis C virus (HCV) who are in jail start and complete treatment more easily.
- Conditions
- HEPATITIS C (HCV), Incarceration, Injection Drug Use, Implementation Science
- Trial name
- MINMON-J (NCT06953479)
- Testing
- Sofosbuvir / Velpatasvir Oral Tablet [Epclusa], Community Health Worker
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Lifespan
Hepatitis C, Chronic
Antiviral Effect, Safety, and Pharmacokinetics of BI201335 +PegIFN/RBV in HCV-GT1 (SILEN-C1&2)
The objective was to investigate the antiviral effect, safety, and pharmacokinetics of BI 201335 (Faldaprevir), given as a soft gelatine capsule, in patients with hepatitis C virus (HCV) genotype 1 infection.
- Trial name
- NCT00774397
- Testing
- BI 201335 NA 240 mg QD / LI, PegIFN/RBV, BI 201335 NA 120mg QD / LI
- Where
- 100 sites in United States, Argentina and 13 more
- Volunteers
- 719 people
- Sponsor
- Boehringer Ingelheim
Chronic Hepatitis c Genotype 1
Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Sofosbuvir in Treatment-naïve Patients With Chronic Hepatitis C Genotype 1
Multicenter, open-label, phase II safety and efficacy study of all-oral combination of narlaprevir/ritonavir and sofosbuvir in Treatment-naïve Patients with Chronic Hepatitis C Genotype 1.
- Trial name
- NCT04246723
- Testing
- Narlaprevir, Ritonavir, Sofosbuvir
- Where
- 5 sites in Russia
- Volunteers
- 85 people
- Sponsor
- R-Pharm
Hepatitis C
Proof of Concept Study to Determine the Safety and Antiviral Effect of BZF961 With or Without Ritonavir Boosting in Hepatitis C Virus Infected Patients
To evaluate the antiviral activity of 3 days of BZF961. To determine safety and tolerability of BZF961 in HCV patients. To evaluate pharmacokinetics of BZF961 in HCV patients.
- Trial name
- CBZF961X2201 (NCT01825980)
- Testing
- BZF961, Ritonavir
- Where
- 3 sites in United States
- Volunteers
- 54 people
- Sponsor
- Novartis Pharmaceuticals
HIV/AIDS, Hepatitis C
Study of HIV, HCV, APS and Phylogenetics for PWID
This study will determine whether assisted partner notification services (APS) can identify and link to care, the sexual and needle-sharing partners of HIV-infected and HIV/hepatitis C (HCV) co-infected persons who inject drugs…
- Trial name
- SHARP (NCT03447210)
- Testing
- Assisted Partner Services
- Where
- 3 sites in Kenya
- Volunteers
- 4,301 people
- Sponsor
- University of Washington
Hepatitis C, Hepatitis C, Chronic
Effects of Health Literacy and HCV Knowledge on HCV Treatment Willingness in HIV-coinfected Patients
A clinical observational study for patients with HIV co-infected with hepatitis C that investigates the levels of their health literacy, hepatitis C and HIV knowledge.
- Conditions
- Hepatitis C, Hepatitis C, Chronic, HIV/AIDS
- Trial name
- NCT03413696
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- University of California, San Diego
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.